RBC Capital analyst Gregory Renza maintained a Hold rating on MannKind (MNKD – Research Report) on January 3 and set a price target of $5.00. The company’s shares closed yesterday at $3.64.
Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, IDEAYA Biosciences, and Amgen. According to TipRanks, Renza has an average return of 8.6% and a 46.46% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for MannKind with a $7.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.75 and a one-year low of $3.30. Currently, MannKind has an average volume of 2.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind (MNKD) Company Description:
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
- MannKind and Sagard Healthcare sign royalty purchase agreement for up to $200M
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
- MannKind enters into 7th amendment to supply pact with Amphastar
- Liquidia price target raised to $30 from $15 at Ladenburg
